ATLANTA, GA—Using inclisiran (Leqvio; Novartis) as soon as possible in the care of patients with atherosclerotic cardiovascular disease (ASCVD) is associated with sustained lowering of LDL cholesterol ...

New Novartis data show early addition of twice-yearly Leqvio (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting. News ...

EAST HANOVER, N.J., April 6, 2024 /PRNewswire/ -- Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio ® (inclisiran) to maximally tolerated statin therapy ...

Novartis may have emerged victorious from a bidding war for MorphoSys, but a peek into the deal negotiations reveals that the Swiss pharma would have been happier if it could have walked away with ...

The lawsuit, filed last week , opens new tab in Alameda County, California state court, also names the University of California, alleging that a now-deceased professor helped Novartis promote ...

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and ...

Novartis, which once had as many as seven different ... Other innovations over the past few years include drugs such as Inclisiran, a new anti-cholesterol drug, and Pluvicto, which deals with ...

David Soergel, global head of cardiovascular, renal and metabolic drug development, Novartis, said: “This study adds data from a real-world setting to the growing body of evidence for Leqvio… and ...

The job eliminations are separate from a restructuring programme which could lead up to 8,000 of Novartis's 78,000 global workforce being cut, it said. Rival Swiss drugmaker Roche (ROG.S ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...